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Part I. Introduction to sequencing technology
On April 15, 1953, Francis Crick and James Watson proposed 
the double helical structure of the DNA molecular structure 
[1]. Since then, methods have been devised to determine 
the sequence of DNA residues, which serves as a blueprint of 
organism. A conventional sequencing means the Sanger-type 
sequencing, which is capillary-based, laboratory-intensive work. 
The human genome project (HGP) accelerated progress in 
sequencing, but sequencing remained a cumbersome procedure 
despite of its importance.
The first commercial next-generation sequencing (NGS) was 
launched in 2005 [2], about 50 years after the discovery of the 
DNA structure by Crick and Watson. Although NGS is the current 
generation sequencing method, it does not have a prototype 
model/platform yet. Generally it refers to a type of sequencing 
that does not need bacterial artificial chromosome cloning but 
runs automatically based on enzymological amplification [3]. 
Alternatively, high-throughput sequencing or massively parallel 
sequencing is often used to describe extremely vast amounts 
of outputs. The Roche/454 FLX Titiniaum and the Illumina/
HiSeq2000 are the most commonly available platforms.
Recently a new sequencing method termed next-NGS (NNGS) 
or no-amplication NGS had been developed. Compared to NGS, 
NNGS requires no amplification step; therefore it is a single-
molecular-based technology, hence it is often defined as the 
third generation sequencing replacing the first generation 
automated Sanger method and the second generation NGS 
[4]. Helicos is the first commercially available NNGS platform 
but Pacific Bioscience is emerging as a new pathfinder. An even 
newer fourth generation sequencer has been developed, which 
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is a platform that enables sequencing without imaging. Up to 
third generation sequencing, sequencers depend upon enzymatic 
cascade and optical (fluorescence) detection, which is high-
cost-and-low-efficiency. Ion Torrent is the first fourth generation 
sequencer, making a breakthrough by utilizing digital detection on 
chips.
The main driving force behind the development of new 
generations of sequencers has been the reduction of cost. The-
thousand-dollar-human-genome has been a catchword for the 
new sequencing technology. DNA sequencing costs has been 
decreasing at a very high rate [5]. Note that the HGP cost $3 billion 
and now it is estimated to cost less than $1,000 within a few 
years. Nonetheless, sequencing the whole genome is expensive 
and cost-ineffective. An alternative approach is to sequence 
specific regions of DNA rather than whole genomes, a strategy 
called targeted sequencing. For example, exome (-targeted-) 
sequencing, which focuses on the exome (exonic regions, which 
is ~5% of human genomes) has been popular because of its 
effectiveness to identify potential mutations. More than 20 rare 
Mendelian disorders have been identified so far utilizing this 
method, including Miller syndrome (family-based design) [6], 
Kabuki syndrome (unrelated individuals) [7], and even a set of ion 
channel mutations believed to cause Mendelian disorders. See [8] 
for a review on recent works.
From the technological point-of-view, the in vitro cloning step 
clonally amplified polymerase chain reaction (PCR) enabled NGS 
due to its time-saving processing. The most common methods 
are emulsion PCR (emPCR) and bridge PCR. emPCR is a method 
for DNA amplification using waters and oil emulsion to amplify 
without loss of DNA molecules. Bridge PCR is performed on a slide 
where affixed primers provide series of DNA amplification. Clonally 
amplified PCR has opened a new era in NGS but ironically it is 
destined to discontinue due to development of single-molecular-
based sequencing technology. For a comprehensive review of the 
sequencing techniques, please refer to [9-11].
Regardless of different platforms that use diverse tactics to 
shorten time and cost, the only product and by-product obtained 
from sequencing is read. Read, or sequence tag is a very short 
DNA sequence that is assumed to be a copy of the true genome 
sequence. In practice, however, it also contains footprints of 
individual variants and systematic errors of current platforms. The 
short length of the read was recognized as one of the obstacles of 
early NGS technology. The first read sequence of Solexa (Illumina, 
USA) was 20-30 bases on average, which could be likened to 
like assembling 10
8-piece puzzle sets to reconstruct the human 
template. Even though the Sanger method still produces relatively 
long reads (300-1,000 bases), a short read length is not a barrier 
anymore for some platforms: the 454 FLX Titanium (Roche, USA) 
produces 400 bases, and the PacBio RS (Paciﬁc Biosciences, USA) 
produces 1,000 bases on average. Also, Illumina (USA) has been 
successfully proven that rather short sequences (e.g., 50 bases) 
are sufficient for re-sequencing purpose and plausible even for de 
novo sequencing [12]. Currently most reads from NGS are single-
end but there are some modifications for longer read length and 
accurate alignment, such as mate-paired/paired-end, strobed 
reads. Those reads (paired-end or strobed read) acquire local 
positional information and tell reads located nearby, whereas 
single-end reads are only aligned to one position on the genome 
like an island. There are subtle differences between mate-paired 
(library) and paired-end (sequencing) in terms of how the library is 
made [13].
Beside the length of read, another aspect to consider is the 
amount of reads. The (average) coverage is defined as the 
average number of times a position in the genome is actually 
sequenced. In rare cases, the percent coverage is used to 
represent the percentage that a position is sequenced at least 
once. Reads are chopped randomly as shotgun style and there 
are repeated regions in the genome like retrotransposon. It 
is, therefore, generally agreed that at least 20-30 coverage is 
required to resequence the human genome acceptably. It should 
be noted that coverage is not uniformly distributed, possibly for 
several reasons: not randomly sheared fragment, not uniformly 
amplified DNA molecules due to genomic sequences composition 
differences [14] or chromatin status [15].
Having sufficient reads is not the only important issue in 
sequencing and bioinformatics. After obtaining reads, proper 
modeling plays an essential role in dissecting data to abstract 
important results from a vast amount of sequencing output. 
For example, assembly and alignment is the key procedure to 
match a read into its real location in the genome. See [16] for 
computational resources like clouding computing and [17, 18] for 
sequence-specific analysis and integrative approach.
Part II. Platform comparisons
As of July 2011, 6 sequencing platforms are commercially 
available. Table 1 summarizes distinctive attributes of some 
sequencing platforms. See [13] for the most updated comparisons 
in terms of technical aspects.apallergy.org
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Each sequencing platform has its advantages and deficiencies. 
It is sometimes recommended to combine data from different 
platforms to overcome limitation and maximize efficiency [19].
Part III. Applications 
Box 1. Sequencing Application 
Depending on input materials: Genome sequencing, RNA-
seq (transcriptome, exome), ChIP-seq (methylome, transcript-
DNA binding), small-RNA-seq (miRNA, piRNA, siRNAs), and ClIP-
seq (transcript-RNA binding) [20].
Depending on purpose: de novo sequencing, (targeted) 
re-sequencing for variants and structural variants detection, 
transcriptome analysis, epigenetic changes and methylation 
pattern, Metagenomics including Microbial diversity and 
Paleogenomics, and so on.
Medical interests mostly focus on re-sequencing to find variants 
linked with diseases or specific phenotype. Some large-scale 
projects are listed below.
- The Cancer Genome Atlas project was launched by the 
National Cancer Institute and the National Human Genome 
Research Institute to provide genetic underpinning of cancer by 
extensive sequencing. Data is open to the research community. 
Recently it released detailed ovarian cancer data confirming that 
the mutation of TP53, BRCA1 and BRCA2 are highly associated with 
ovarian cancer [21].
- The 1000 Genomes Project started to provide understanding 
of the human genome variants (SNPs, structural variants, and their 
haplotypes) from population-scale sequencing by international 
collaboration. In 2010, the project reported its pilot phase and the 
updated data are released monthly. For the details of the 1000 
Genomes Project, refer to [22] presenting the overview of human 
genome sequence variation studies and the pilot phase of the 
project.
- Metagenomics of the Human Intestinal Tract project aims to 
link human health and intestinal microbiota. The human gut has 
the potential to diagnose the health of individuals and a large 
study was done defining the minimal gut metagenome of 124 
European individuals [23].
- The International Rare Disease Research Consortium, launched 
in early 2011 aiming to diagnose rare diseases by 2020, announced 
€100-million (US $140-million) call for research proposals [24].
There are several next-generation studies based on new 
techniques. For example, a web-based genome-wide association 
study was done by one direct-to-consumer (DTC) company. 
In many cases, medical science is slow. Multicenter genetic 
study on Parkinson’s diseases spanned 6 years [25]. Now it 
can be reproduced within about 1 year once the cohort was 
constructed from the customer database of the personal 
genetics company [26]. Of course, this study was approved by an 
external IRB. Another good example is integration of genome-
sequencing analysis and social-network analysis [27]. This study 
is a convergence of the classical and the modern. Combining 
Table 1. Comparison of sequencing platforms
454 FLX + HiSeq 2000 PacBio RS Ion Torrent 316
Company Roche (USA) Illumina (USA) Paciﬁc Biosciences (USA) Life Technologies (USA)
Sequencing method
Synthesis 
(pyrosequencing)
Synthesis
(cyclic reversible terminator)
Realtime sequencing
Synthesis (H
+ detection) on 
the chip
Amplification emPCR BridgePCR None emPCR
Run time 23 h 11 days (dual flow cell)  0.5 - 2 h 2 h
Reads  Mb/run 1,000 540,000-600,000     5 - 10 >100
Reagent cost/run $6,200 ~$20,000 $110 - 900 $750
Reagent cost/Mb $7 >$0.04    $11 - 180 <$7.5
Read length 500-1,000 (mode 700) 2*100 (paired-end reads)       860 - 1,100 >200
Primary errors Indel Substitution CG deletion Indel
Pros Long read length
Highest throughput and 
lowest cost per Mb
Longest read length, no 
amplification error
Low cost per sample 
Cons
High capital cost and  
high cost per Mb
High capital cost and 
high computation needs
Error rates, comparatively 
small outputs, high cost per 
Mb
High cost per Mbapallergy.org
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sequencing and epidemiology uncovered a tuberculosis outbreak. 
The analysis comprised relatively very small bacterial sequencing, 
social-network questionnaires from 41 patients, and a linked-
network model.
Apart from the academic challenges stated in previous 
paragraphs, business models such as the personal genome 
industry or DTC have been using sequencing. If you want to 
know yourself, DTC companies such as 23andMe, deCODEme and 
Navigenics will calculate a set of disease risks under $500 once you 
provide DNA samples, like saliva or a cheek swab. However, you 
might want to read J. Craig Venter’s opinion for current limitations 
[28].
The human leukocyte antigen (HLA) polymorphism detection 
is a specific application of sequencing for diagnosis. Many genes 
located in the major histocom patibility complex (MHC) on 
chromosome 6 are related to immunological functions such as 
HLA expression. Clinically, matching HLA haplotypes is essential 
for further therapy of bone marrow transplanting. The comparison 
between the first generation Sanger sequencing and the second 
generation NGS was done from the study on HLA polymorphism 
[29]. Comprehensive comparison results from selected genes (Class 
I and II genes) showed that NGS outperforms the conventional 
Sanger method in terms of timing and cost but there are still 
considerable issues regarding notable sequencing alignment error 
and the need for intensive computational support. Another effort 
on sequencing MHC region showed that direct sequencing of the 
whole gene regions can reveal several variants in Tubulin beta of 
patients with acute myeloid leukaemia undergoing HLA-matched 
allogenic hematopoietic stem cell transplantation [30]. 
Summary 
Massively parallel sequencing guides us to new phase of 
medical research and application. For example, detection of 
rare single nucleotide variants is a direct clinical usage of new 
sequencing technology. It also enables to diagnosing structural 
variants detection such as chromosome rearrangement or 
genome-wide variants from somatic diseases like cancer [31, 32]. 
There is no standard platform and researchers should consider 
the capacities of different platforms depending upon the aim of 
research. As the cost of sequencing is gradually decreasing and 
more integrative work is being developed, we will gain deeper 
understanding of human biology. A new paradigm of clinical 
study is about to begin.
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